SS Innovations International (SSII) Stifel 2025 Healthcare Conference summary

Company overview and technology differentiation

• Achieved rapid growth since inception, with Nasdaq listing in April and a market cap between $1.3–$1.5 billion.

• Developed the SSi Mantra system, a modular, multi-specialty robotic platform with unique features such as five-arm capability, advanced AR/VR, and 3D vision for all users.

• Over 127 systems installed in 8 countries, with more than 6,000 procedures performed and zero device-related adverse events.

• System supports a full spectrum of procedures, including cardiac and pediatric, with 20+ cardiac-specific instruments.

• Strong leadership and advisory board with deep experience in robotics, surgery, and public company management.

Market opportunity and growth strategy

• Global addressable market projected to reach $16.8 billion by 2031, with India alone representing a $4 billion opportunity.

• Less than 1% of global surgical volume currently uses minimally invasive robotic techniques, mainly due to high costs and limited access.

• Focus on affordability and modularity enables penetration into Tier 2 and Tier 3 cities and ambulatory surgery centers.

• Expansion ongoing, with systems entering Oman, Dubai, Greece, and Central Asia; 20+ registration processes underway.

• U.S. FDA and European approvals targeted for first half of next year, aiming for global market penetration.

Clinical and operational highlights

• Over 1,400 surgeons trained, with a short learning curve for users familiar with other systems.

• Teleproctoring and telesurgery capabilities allow remote guidance and operations, including successful cardiac procedures performed from thousands of kilometers away.

• Proprietary instruments and consumables expected to drive recurring revenue as installed base grows.

• System outperformed da Vinci in India, selling more than double the number of systems in 2023.

• Cash flow positive, with significant quarter-on-quarter and year-on-year revenue growth.